Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Systemic lupus erythematosus
•
Pediatric Rheumatology
In patients with possible early SLE or undifferentiated disease can multiomics be used to help predict what disease phenotype they will develop?
Related Questions
Would you consider combination belimumab and anakinra for a patient who has SLE and MAS?
If a patient is legally blind and on hydroxychloroquine, do you still recommend follow up with ophthalmology to monitor for hydroxychloroquine retinal toxicity?
How would you approach potentially tapering maintenance mycophenolate mofetil in a patient with a history of class IV LN that has been in remission for >5 years?
Would you pursue immunosuppression in a patient with mixed connective tissue disease presenting primarily as dysautonomia assuming other causes have been ruled out?
How should rheumatologists address the impact on patients who are initially diagnosed with SLE based on positive ANA, but later reclassified as having UCTD?
How do you approach a patient with high titer ANA and a new diagnosis of ITP, but no other signs or symptoms suggestive of active rheumatologic disease?
Would you continue belimumab in high risk lupus patients with overlapping scleroderma features with ILD who become pregnant and who are already on HCQ and azathioprine?
What parameters would you use to decide whether to stop hydroxychloroquine in a patient whose lupus is well controlled but is found to have a prolonged QT interval on routine EKG?
What factors drive you to prioritize treatments that inhibit T cells vs B cell depletion when choosing therapies for patients with refractory SLE?
Do you always pursue testing for NOD2 mutations when you are suspecting a diagnosis of Blau syndrome?
